drugset / Trial / NCT06690775
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Phase 2
Recruiting
230 enrolled
TORL Biotherapeutics, LLC
European Network of Gynaecological Oncological Trial Groups (ENGOT) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
Timeline
- Start
- 2024-11-20
- Primary completion
- 2027-10
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TORL-1-23 | Other / unclassified | 2.4 mg/kg | Intravenous |
| Subject | TORL-1-23 | Other / unclassified | 3 mg/kg | Intravenous |
| Subject | TORL-1-23 | Other / unclassified | 3.4 mg/kg | Intravenous |
| Background | Pegfilgrastim | Protein / enzyme biologic | 6 mg | Subcutaneous |